Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07290569 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis

Study acronym: EVERLAST-B
StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Enrollment closed, study ongoing Site details revised at 36 of 36 sitesv7 Show 1 more changeShow less
    • Site details revised at 36 of 36 sites
  2. Site details revised at 1 of 36 sitesv6
  3. Trial sites expanded: 26 → 36 locationsv5
  4. Study sites: 25 to 26v4
  5. Study sites: 21 to 25v3
  6. Study sites: 9 to 21v2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a multicenter, randomized, double-blinded, placebo-controlled, dose-range finding study to evaluate the efficacy and safety of ORKA-001 in adult participants with moderate-to-severe plaque psoriasis.
Trial Details
NCT Number NCT07290569
Lead Sponsor Oruka Therapeutics, Inc.
Conditions Plaque Psoriasis
Enrollment 160 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov